Cargando…
Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance
BACKGROUND: Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting ‘recent’ HIV infection in cross-sectional incidence estimation. This study assesses and compares the performance of the two as...
Autores principales: | Sempa, Joseph B., Welte, Alex, Busch, Michael P., Hall, Jake, Hampton, Dylan, Facente, Shelley N., Keating, Sheila M., Marson, Kara, Parkin, Neil, Pilcher, Christopher D., Murphy, Gary, Grebe, Eduard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660077/ https://www.ncbi.nlm.nih.gov/pubmed/31348809 http://dx.doi.org/10.1371/journal.pone.0220345 |
Ejemplares similares
-
Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis
por: Sempa, Joseph B., et al.
Publicado: (2022) -
Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository
por: Facente, Shelley N., et al.
Publicado: (2019) -
Development of an international external quality assurance program for HIV-1 incidence using the Limiting Antigen Avidity assay
por: Keating, Sheila M., et al.
Publicado: (2019) -
Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection dating
por: Facente, S. N., et al.
Publicado: (2020) -
Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting “Recent” HIV Infection and Calculating Population Incidence
por: Keating, Sheila M., et al.
Publicado: (2016)